FT : Luxury hotel chains join the daytime rush

Traditionally, room rental by the hour has been the preserve of seedy establishments or, more recently, “love hotels” found in countries from Argentina to Japan. But luxury hotel groups have embraced the hourly model in France.

Hotel chains, including Accor and Marriott, have signed up to a French start-up online booking platform called Dayuse.com, with the number of hotels in France using the service doubling to 600 this year, according to the company.

“Hotels in France have been struggling, but we are offering them another source of revenue,” says David Lebée, the founder and chief executive of dayuse.com. “Ten years ago hotels would not have dreamt of doing this, but times change.”

According to Dayuse, which launched in 2010, 70 per cent of rooms are empty during the day and it says has generated more than $20m in revenue for those hotels signed up to its service. Accor and Marriott confirmed that they have signed up to the service, although declined to comment further.

Maud Ruault, the manager of Les Plumes, an independent Paris hotel signed up to Dayuse, says the site brings in 30 to 40 bookings a month, and has been a “great source of new business” at a “difficult time”, referring to the drop in bookings prompted by a spate of terrorist attacks in France.

“People are not there to sleep, they want an experience . . . Many are couples who want to have fun without their children,” she says, adding that users are mostly domestic customers rather than tourists.

On the site customers can, for example, rent an €800-a-night room at the four-star Marriott Opera Ambassador in central Paris for €99 between 11am and 4pm. To have a “Love Box” filled with adult toys is an extra €40 and a bottle of Champagne €70.

The increasing adoption of Dayuse comes as terrorist attacks in France have hit profits across the country’s hotel industry, with the number of tourists visiting the country falling steeply.

Accor, Europe’s largest hotel operator, reported a 4.7 per cent fall in revenue in France in the third quarter because of a “climate of insecurity since the beginning of the year”. Jean-Jacques Morin, chief financial officer of Accor, said fears of terrorism had “massively affected leisure travel” to France.

This shows little signs of changing. The summer was “catastrophic” for hotels in France, according to Deloitte, with occupancy rates down and revenue per available room — the industry’s preferred sales measure — falling 28 per cent in August for mid-range hotels and 48 per cent for luxury and palace hotels. In September and October rates fell further still.

Hoteliers in France are also being squeezed by digital upstarts such as Airbnb, which can turn any home into a competing mini-hotel. They are being challenged as well by online travel agents such as Booking.com and Expedia, which have hurt brand loyalty.

Mr Lebée estimates that Airbnb and similar rental sites have led to a 15 per cent fall in revenues on average across the hotel industry, and that signing up to Dayuse can restore 10 per cent of this by opening up a new income stream.

He says that there are couples — “faithful or unfaithful” — who use the service for “discrete rendezvous”, but there are also business people looking for a place to conduct interviews or travellers wanting to relax before a late flight.
Jean-Bernard Falco, the head of AhTop, an industry group for the hotel sector, says that renting out rooms during the day is just “one solution” to improving the fortunes of the French hotel industry.

AhTop is trying to pressure lawmakers to tighten rules governing home-sharing websites such as Airbnb, wanting them to make it harder for renters to avoid taxes and also for them to pay more taxes on their rental income.

Dayuse late last year closed a €15m fundraising with venture capital firms Idinvest Partners and Partech Ventures. It is supported by angel investors Paul Dubrule, the co-founder of Accor and Charles Petruccelli, the former chief executive of American Express Travel.

The company has 3,000 hotel partners in 16 countries. It says it wants to have a presence in 50 countries by 2020. This year the company also signed up Mövenpick, a Swiss hotel company.

WSJ : Euro Surges Mysteriously in Thin End-Year Markets

Euro Surges Mysteriously in Thin End-Year Markets
Analysts are at loss to explain brief rise against U.S. dollar and other currencies

SYDNEY—The euro rallied sharply in Asia trading Friday, climbing more than two U.S. cents in a move that had traders scratching their heads.

The euro jumped from around $1.0490 to briefly trade above US$1.0700 in a matter of moments—its highest level in two weeks—against a backdrop of thin year-end markets.

The euro’s short-lived surge also lifted the U.K. pound and the Australian and New Zealand dollars, traders said.

At 0310 GMT, the euro was trading at $1.0531. The British pound jumped from $1.2250 to $1.2309, before pulling back to around $1.2278.

Before the spike in the euro, the pound was part of broad market strength against the U.S. dollar, which was under pressure amid end-of-year book squaring and profit-taking.

Overnight, the WSJ Dollar Index, which measures the U.S. currency against 16 others, fell 0.5% to 93.06. Despite the overnight slide, the dollar is on track to end 2016 with a gain of more than 3%.

Ray Attrill, global head of currency strategy at National Australia Bank, said that trying to explain the move would be folly.

“Whether somebody accidentally pressed a button or algo trades were triggered, nobody knows,” Mr. Attrill said.

“If they tell us anything about what January has in store, it may be that it’s going to be a choppier ride for the dollar relative to the cozy dollar-bullish consensus that prevailed in the run up to Christmas,” he added.

Elias Haddad, senior currency strategist at the Commonwealth Bank of Australia, agreed there wasn’t much to explain the euro’s sudden rise.

“Volume is too thin right now to draw any conclusion from this move,” he said.

Asian currencies largely escaped the volatility and were little changed.

Reuters (Yest.) J&J discussing breaking up Actelion in an acquisition - sou


Johnson & Johnson (JNJ.N) is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd (ATLN.S) that would separate its commercialized portfolio from its research and development assets, people familiar with the matter said on Thursday.

The deal structure would allow J&J to acquire Actelion with a cash offer in the region of $260 per share, a little more than what it had offered when it walked away from negotiations earlier this month. It also would allow Actelion shareholders to benefit financially from Actelion's R&D pipeline, the people said.

Under the deal being discussed, Actelion's R&D pipeline would be placed in a new publicly traded company, the people said. The exact ownership of the new company, and whether Actelion Chief Executive Jean-Paul Clozel would head it, are among the details still being negotiated, the people said.

A deal could be finalized by late January, they said, cautioning that negotiations could still end unsuccessfully. The sources asked not to be identified because the details are confidential.

J&J and Actelion declined to comment.

Actelion shares ended trading in Zurich on Thursday near flat at 229.90 Swiss Francs ($224.6), giving the company a market capitalization of $23.5 billion. J&J shares were up 0.5 percent at $115.62, giving it a market capitalization of $315 billion.

Actelion said last week it had entered into exclusive talks with J&J about a strategic transaction. J&J had pulled out of negotiations with Actelion over price disagreements earlier this month, temporarily allowing France's Sanofi SA (SASY.PA) to engage in one-on-one acquisition talks with Actelion.

Clozel, who worked for Roche Holding AG (ROG.S) for 12 years before founding Actelion in 1997, and his wife, Chief Scientific Officer Martine Clozel, have built up a world-leading drug portfolio at Actelion to treat pulmonary arterial hypertension. The company is Europe's biggest biotechnology drug maker.

Actelion's Opsumit and Uptravi drugs to treat the life-threatening condition of pulmonary arterial hypertension could generate more than $4.6 billion in combined 2020 sales, analysts forecast, up from an estimated $1.4 billion this year.

J&J has said the company is exploring acquisitions to expand its main consumer, medical device and pharmaceuticals segments. J&J's biggest product, the arthritis drug Remicade, faces cheaper competition from Pfizer Inc (PFE.N).

Actelion also has new drugs for multiple sclerosis and clostridium difficile, but regulatory approvals for those are years away.

FT : Brexit transition deal may avert UK economic ‘catastrophe’

Brexit transition deal may avert UK economic ‘catastrophe’
Top EU lawyer says trade pact within 2 years is ‘totally impossible’

It will be “totally impossible” for Britain to wrap up a trade pact with the EU within two years and a transition deal will be needed to avert “a catastrophe” for the British economy, according to one of the EU’s most eminent lawyers.

Jean-Claude Piris, the head of the EU Council’s legal service from 1988-2010, said a trade deal would comprise “thousands of pages and hundreds of articles” and there was no chance of it being completed before a scheduled Brexit in 2019.

The comments by Mr Piris, the legal architect of a succession of EU treaties from Maastricht to Lisbon, directly contradict claims by Theresa May, Britain’s prime minister, that both a divorce deal and a trade accord can be signed within two years of Article 50 being triggered.

“I would expect us to be able to negotiate a deal in the two-year period that has been set out,” Mrs May told MPs on December 20. David Davis, Brexit minister, has made the same claim.

Mr Piris said in an interview that putting in place a UK-EU trade deal “could take up to 10 years” because of the complexity of the task, but added that he hoped it could be concluded more quickly. “We could do it in maybe five years, I don’t know.”

In any event he said there would be an inevitable gap between the scheduled date of Brexit in spring 2019 and the entry into force of a trade deal. He said that could cause serious economic damage unless a stopgap arrangement was put in place.

“You vitally need a transition period,” he said. Mr Piris said the interim arrangement was needed to stop the UK falling into the “WTO gap” — where it applied the rules of the World Trade Organisation until the free-trade agreement came into force.

Asked whether a trade deal could take a decade to complete and ratify, Mr Piris said: “It’s not the most pessimistic view because the most pessimistic view is that there will be no agreement at all.

“It will take years, that’s for sure. I don’t know how many years . . . some people say between four and eight years but that is if people have goodwill on both sides.

“The important thing is that clearly there is a gap of a few years between the date where the UK is withdrawing from the EU and the date where this agreement comes into effect, perhaps five or six years.”

Mr Piris said the “WTO gap” would be “a catastrophe for the EU” but mainly for Britain because it did nearly half of its trade with Europe.

“There will be the customs tariffs, there will be controls at the borders and so forth,” he said. “The UK will also lose the benefits of trade agreements made by the EU with 60 countries in the world. You’ll lose also the financial passport.”

Mr Piris said there were two kinds of transitional deal to bridge the gap, the first of which would see Britain staying in the single market for a few years.

But he said that would require Mrs May to sign up for a limited period to existing obligations including the jurisdiction of the European Court of Justice and free movement of people — both of which she has said are red lines in her negotiation.

Mr Piris said the second option was “much more modest” where Britain negotiated to stay in the customs union, similar to the deal enjoyed by Turkey, a non-EU member which has a customs agreement with the EU.

“That would mean the territory of the UK would be in the customs union and you benefit from the whole of the EU’s trade policy including all the agreements we have done in the past and the ones we are going to conclude soon with Japan and so on.”

That would also mean that Britain’s ability to strike trade deals on its own terms would be severely limited during the transition as it would have to apply the trade deals and external tariffs set by Brussels

>>> What to look at today - 30th of December 2016

Dow-0.07% S&P-0.03% Nasdaq -0.12% Russell +0.17%
US Mkt closed slightly lower. Five cyclical sectors ended in negative territory, which overshadowed solid gains among lightly-weighted countercyclical groups like utilities (+1.3%), real estate (+0.9%), and telecom services (+0.4%). To be fair, the influential health care sector (+0.1%) also registered a modest gain, but biotechnology could not keep up. Energy (-0.2%) retreated amid a 0.6% decline in crude oil, which slid to $53.74/bbl after yesterday's bearish reading of the API inventory report was confirmed by today's data from the EIA. Financials underperformed also. Volume remained lights wit less than 700mil shares traded. US After Hours MYL +2% on generic Concerta launch news... INNL down nearly 50% after FDA rejected its XARACOLL application. Nikkei225 underperforms yet again as profit-taking in USD/JPY continues; USD falls to 2-week lows against JPY and EUR - the move against the latter particularly abrupt with about a 150pip spike to 1.0650 during the most illiquid early part of the Asia session. No specific catalysts for the move cited by dealers outside of algo-driven buying. China regulators called for tighter criteria on investment in insurers. local press also speculated the govt could further raise coal and steel capacity reduction goals by 10% in 2017 after completing initial 2016 targets ahead of schedule. Toshiba bounced after about a 40% plunge this week; Nomura says the US nuclear ops writedown is priced in.

Nikkei -0.16% Hang Seng +0.96% CSI +0.36% +0.25%

Eur$ 1.0533 CNH 6.9732 CNY 6.95 JPY 116.81 GBP 1.2275 CHF 1.0193 RUB$60.6020 WTI$ 54.02 +0.46%

S&P +0.23% EuroStoxx +0.03% FTSE -0.02% Dax +0.10% SMI +0.11%


Macro :
- Italy Wins EU Nod to Extend Bank Liquidity Program
- Italy Antitrust Chief Urges EU States to Combat Fake News: FT
- U.K. to Ask for Central Role in Europol After Brexit: Telegraph
- French Court Bans ‘Google Tax’ Measure on Diverted Profits

Keep an eye on :
- ATLN VX : J&J Said to Discuss Breakup of Actelion in Acquisition: Reuters
- DBK GY : Deutsche Bank Robo-Adviser Has Fewer Than 100 Customers: Spiegel
- DNB NO : DNB CEO Bjerke Says Consumer Debt Growth Rate Unhealthy: DN
- ENI IM : Eni Shuts Goliat Production After Damage to Offloading Hose
- FCA IM : Fiat Said to Be Developing Autonomous Vehicle: The Information
- FCT IM : Vard Rises Back to Fincantieri’s Delisting Price on Extension
- HMSO LN : Hammerson Sells 50% of Watermark Development to GIC for GBP48.5m
- MYL US : Mylan Rises Post-Market on U.S. Release of Generic Concerta
- RBS LN : RBS Shareholders Urge Bank to Create Investor Committee: FT
- REP SM : Repsol in Talks to Sell Algeria Well Stake: El Economista
- ROG VX : Roche Gene-Sequencing Acquisition Founder Accused in Patent Suit
- SCYR SM : Sabadell Becomes Sacyr Shareholder With 2.37% Stake: Expansion
- TEC FP : Technip, Venezuelan Firms Picked for Aruba Refinery Job: Reuters

>>> US After Hours Summary: MYL +2% on generic Concerta launch news...


After Hours Summary: MYL +2% on generic Concerta launch news... INNL down nearly 50% after FDA rejected its XARACOLL application

After Hours Gainers:

  • MYL +2.2% (launches generic version of Janssen's Concerta tablets)
  • NVDA +1.2 (edging higher in extended trade after recouping early losses and closing near highs)
  • AG +1.2%, MBLY +1.0% (continued strength)

After Hours Losers:

  • INNL -49.2% (light volume; Innocoll received FDA Refusal to File letter for XARACOLL - its product candidate for postsurgical pain treatment)
  • GEVO -8.6% (announces 1-for-20 reverse stock split)

>>> Asian Update

Asia Mid-Session Market Update: USD craters to 2-week lows against EUR and JPY while Gold adds to gains; China's NDRC said to loosen investment curbs on banking

***US Session Highlights***
- (US) NOV ADVANCE GOODS TRADE BALANCE: -$65.3B V -$61.6BE
- (US) NOV PRELIMINARY WHOLESALE INVENTORIES M/M: 0.9% V 0.2%E
- (US) Nevada reports Nov casino gaming Rev $930.4M, -1.5% y/y; Las Vegas strip rev $517M, -3.5% y/y
- (US) 7-Year Treasury $28 billion auction average yield 2.284%, prior 2.215%, Bid-To-Cover ratio: 2.54 V 2.68 prior and 2.50 average over last 12 auctions.

***US markets on close: Dow -0.1%, S&P500 flat, Nasdaq -0.1%***
- Best Sector in S&P500: Utilities
- Worst Sector in S&P500: Financials
- Biggest gainers: NEM +7.6%; DLR +2.5%; ETR +2.1%
- Biggest losers: CMG -2.3%; MU -2.2%; CFG -2.0
- At the close: VIX 13.4 (+0.4pts); Treasuries: 2-yr 1.22% (-3bps), 10-yr 2.48% (-3bps), 30-yr 3.08% (flat)

***US movers afterhours***
- MYL: Launches generic Concerta (methylphenidate) tablets; +2.2% afterhours
- NVDA: TheStreet.com defends NVDA with analysis of Citron claims; +1.7% afterhours
- GEVO: Announces 1-for-20 reverse stock split, effective Jan 5th; -8.5% afterhours
- INNL: Receives refusal to file letter from FDA for Xaracoll (bupivacaine HCl collagen-matrix implants) New Drug Application; -49.7% afterhours

***Key economic data***
- (KR) SOUTH KOREA DEC CPI M/M: 0.1% V 0.2%E; Y/Y: 1.3% V 1.3%E; CPI CORE Y/Y: 1.2% V 1.4%E
- (AU) AUSTRALIA NOV PRIVATE SECTOR CREDIT M/M: 0.5% V 0.5%E; Y/Y: 5.4% V 5.4%E
- (TH) Thailand Dec PMI Manufacturing: 50.6 v 48.2 prior; first expansion since April

***Asia Session Notable Observations, Speakers and Press***
- Nikkei225 underperforms yet again as profit-taking in USD/JPY continues; USD falls to 2-week lows against JPY and EUR - the move against the latter particularly abrupt with about a 150pip spike to 1.0650 during the most illiquid early part of the Asia session. No specific catalysts for the move cited by dealers outside of algo-driven buying.
- New Zealand and Australia main indices end the day early, finishing 2016 up 9% and 7% respectively.
- Economic data were primarily 2nd tier, not yielding any meaningful market impact. South Korea CPI y/y was in line w/ consensus at 1.3%, but below BOK's 2% target for 38th consecutive month.
- China regulators called for tighter criteria on investment in insurers, while state planner NDRC said govt would loosen foreign investment curbs in banking. Ahead of the open, local press also speculated the govt could further raise coal and steel capacity reduction goals by 10% in 2017 after completing initial 2016 targets ahead of schedule.
- Toshiba bounced after about a 40% plunge this week; Nomura says the US nuclear ops writedown is priced in.

China:
- (CN) China Insurance Regulatory Commission (CIRC) proposes to tighten rules on investment stakes in insurers - financial press
- (CN) China State Planner (NDRC) official: China to loosen foreign investment curbs in banking sector
- (CN) PBoC requests banks to report yuan trading over CNY50K vs CNY200K previously; effective July 1st 2017
- (CN) SocGen chief China economist: China State Council may abandon 6.5% GDP growth target by 2018 to curb asset bubbles and financial leverage - press
- (CN) China reportedly could raise coal and steel capacity reduction goals by 10% in 2017 - Chinese press

Japan:
- (JP) Japan 2016 vehicle sales seen at 4.97M units, -2% y/y and a 5-year low - Nikkei
- (JP) Japan PM Abe's cabinet approval rating rose 6pts to 64% (38-month high) following his joint visit with US Pres Obama to Pearl Harbor - Nikkei

Australia:
- (AU) NAB co-head of FX strategy: There is a chance that US interest rates will exceed those of Australia in 2017, but the effects on AUD exchange rate may be less severe; today's stronger terms of trade implies "a significantly higher level" - AFR

***Asian Equity Indices/Futures (23:30ET)***
- Nikkei225 +0.1%, Hang Seng +1.0%, Shanghai Composite +0.1%, ASX200 -0.6%, Kospi closed
- Equity Futures: S&P500 +0.2%, Nasdaq +0.3%, Dax +0.1%, FTSE100 +0.2%

***FX ranges/Commodities/Fixed Income (23:30ET)***
- EUR 1.0485-1.0650; JPY 116.05-116.90; AUD 0.7215-0.7245; NZD 0.6950-0.6980
- Feb Gold +0.2% at 1,161/oz; Feb Crude Oil +0.3% at $53.94/brl; Mar Copper +0.5% at $2.50/lb
- (CN) China MOF sells 91-day bonds, avg yield 2.674%
- USD/CNY: (CN) PBOC SETS YUAN MID POINT AT 6.9370 V 6.9497 PRIOR; strongest Yuan fix since Dec 19th
- (CN) PBOC to inject CNY160B in 7-day reverse repos, CNY90B in 14-day reverse repos; For the week, drains CNY245B v CNY375B injection in prior week

***Asia equities / Notables / movers by sector***
- Consumer discretionary: Adastria Holdings Co 2685.JP -8.3% (9-month result); Aeon Mall Co.8905.JP -1.9% (9-month result speculation)
- Financials: Wynn Macau 1128.HK +3.3%, Melco International Development 200.HK +5.2% (ahead of Macau Dec revenue data)
- Industrials: China Green Holdings 904.HK +1.1% (H1 result); Takata Corp.7312.JP +21.2% (settlement speculation momentum)
- Technology: Toshiba Corporation 6502.JP +9.9% (Nomura positive note); Inventec Corp 2356.TW +3.0% (benefits from popularity of AirPods)
- Materials: Sandfire Resources SFR.AU -1.2% (management changes); Newcrest NCM.AU +5.1%, Northern Star NST.AU +4.0%, Evolution EVN.AU +9.8%, St Barbara SBM.AU +10.6% (Gold price rises); China Minmetals Resources 1208.HK +2.1% (asset sale)
- Healthcare: Yunnan Baiyao Group Co 000538.CN +10.0% (new investment plan)